Cargando…

Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma

Autologous stem cell transplantation (ASCT) is considered the standard therapy for younger patients with newly diagnosed symptomatic multiple myeloma (MM). The introduction into clinical practice of novel agents, such as the proteasome inhibitor bortezomib and the immunomodulatory derivatives (IMiDs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ria, Roberto, Reale, Antonia, Solimando, Antonio Giovanni, Mangialardi, Giuseppe, Moschetta, Michele, Gelao, Lucia, Iodice, Giuseppe, Vacca, Angelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369512/ https://www.ncbi.nlm.nih.gov/pubmed/22701493 http://dx.doi.org/10.1155/2012/607260

Ejemplares similares

Multiple Myeloma Macrophages: Pivotal Players in the Tumor Microenvironment
por: Berardi, Simona, et al.
Publicado: (2013)

Neutropenia and G-CSF in lymphoproliferative diseases
por: Ria, Roberto, et al.
Publicado: (2013)

Managing myelodysplastic symptoms in elderly patients
por: Ria, R, et al.
Publicado: (2009)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2020)

Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies
por: Ria, Roberto, et al.
Publicado: (2014)

A multiple myeloma that progressed as type I cryoglobulinemia with skin ulcers and foot necrosis: A case report
por: Solimando, Antonio G., et al.
Publicado: (2018)

Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma
por: Ria, Roberto, et al.
Publicado: (2020)

Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance
por: Melaccio, Assunta, et al.
Publicado: (2022)

Microenvironment drug resistance in multiple myeloma: emerging new players
por: Di Marzo, Lucia, et al.
Publicado: (2016)

Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma
por: Lamanuzzi, Aurelia, et al.
Publicado: (2018)

A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche
por: Solimando, Antonio Giovanni, et al.
Publicado: (2020)

Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update
por: Ria, Roberto, et al.
Publicado: (2018)

Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
por: Ria, Roberto, et al.
Publicado: (2020)

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma
por: Ravi, P, et al.
Publicado: (2017)

High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment
por: Solimando, Antonio Giovanni, et al.
Publicado: (2019)

Angiogenesis and Progression in Human Melanoma
por: Ria, R., et al.
Publicado: (2010)

MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance
por: Desantis, Vanessa, et al.
Publicado: (2020)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Acquired platelet dysfunction in newly diagnosed myeloma
por: Mortimer, Joshua, et al.
Publicado: (2021)

A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022)

Giant plasma cells with multiple immature nuclei in a young woman with newly diagnosed multiple myeloma
por: Giudice, Valentina, et al.
Publicado: (2022)

The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain
por: Tang, Hoi Ki Karen, et al.
Publicado: (2022)

Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2022)

Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review
por: McCaughan, Georgia J., et al.
Publicado: (2022)

Functional and Biological Role of Endothelial Precursor Cells in Tumour Progression: A New Potential Therapeutic Target in Haematological Malignancies
por: Reale, Antonia, et al.
Publicado: (2016)

Actors on the Scene: Immune Cells in the Myeloma Niche
por: Leone, Patrizia, et al.
Publicado: (2020)

Suspected Pericardial Tuberculosis Revealed as an Amyloid Pericardial Mass
por: Cicco, Sebastiano, et al.
Publicado: (2018)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Laboratory Features of Newly Diagnosed Multiple Myeloma Patients
por: Hussain, Azhar, et al.
Publicado: (2019)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma
por: Libby, Edward, et al.
Publicado: (2020)

Uptake-Dependent and -Independent Effects of Fibroblasts-Derived Extracellular Vesicles on Bone Marrow Endothelial Cells from Patients with Multiple Myeloma: Therapeutic and Clinical Implications
por: Lamanuzzi, Aurelia, et al.
Publicado: (2023)

Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Evidence for Bone Marrow Adult Stem Cell Plasticity: Properties, Molecular Mechanisms, Negative Aspects, and Clinical Applications of Hematopoietic and Mesenchymal Stem Cells Transdifferentiation
por: Catacchio, Ivana, et al.
Publicado: (2013)

Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSMM
por: Bachmann, Friederike, et al.
Publicado: (2021)

MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease
por: Desantis, Vanessa, et al.
Publicado: (2021)

New Insights into Diffuse Large B-Cell Lymphoma Pathobiology
por: Solimando, Antonio Giovanni, et al.
Publicado: (2020)

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial
por: Bringhen, Sara, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pj7e4pr82hlqa53g1m2n6jkf4s